# Rolf Kiessling

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7498413/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 93 papers | 8,299 citations | 57631 44 h-index | 51492 86 g-index |
| 96 all docs | 96 docs citations | 96 times ranked | 10605 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Selective rejection of Hâ€“2-deficient lymphoma variants suggests alternative immune defence strategy. Nature, 1986, 319, 675-678. | 13.7 | 1,914 |
| 2 | Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508. | 0.8 | 395 |
| 3 | Immature Immunosuppressive CD14+HLA-DRâ¯/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign. Cancer Research, 2010, 70, 4335-4345. | 0.4 | 366 |
| 4 | An Analysis of the Murine NK Cell as to Structure, Function and Biological Relevance. Immunological Reviews, 1979, 44, 165-208. | 2.8 | 349 |
| 5 | Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. European Journal of Immunology, 1996, 26, 1308-1313. | 1.6 | 321 |
| 6 | Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. Clinical Cancer Research, 2014, 20, 4096-4106. | 3.2 | 230 |
| 7 | Tumor-induced immune dysfunction. Cancer Immunology, Immunotherapy, 1999, 48, 353-362. | 2.0 | 208 |
| 8 | Alterations in the signal-transducing molecules of T cells and nk cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. International Journal of Cancer, 1995, 61, 765-772. | 2.3 | 191 |
| 9 | On the armament and appearances of human myeloid-derived suppressor cells. Clinical Immunology, 2012, 144, 250-268. | 1.4 | 168 |
| 10 | Coexpressed Catalase Protects Chimeric Antigen Receptorâ€“Redirected T Cells as well as Bystander Cells from Oxidative Stressâ€“Induced Loss of Antitumor Activity. Journal of Immunology, 2016, 196, 759-766. | 0.4 | 164 |
| 11 | Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2â€“Dependent Mechanisms. Cancer Research, 2013, 73, 3877-3887. | 0.4 | 160 |
| 12 | Camouflage and sabotage: tumor escape from the immune system. Cancer Immunology, Immunotherapy, 2011, 60, 1161-1171. | 2.0 | 150 |
| 13 | Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 2015, 21, 482-491. | 3.5 | 146 |
| 14 | Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. International Journal of Cancer, 2004, 108, 71-77. | 2.3 | 138 |
| 15 | IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood, 2016, 128, 1475-1489. | 0.6 | 136 |
| 16 | The epstein-barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in burkitt lymphoma lines. International Journal of Cancer, 1994, 57, 240-244. | 2.3 | 132 |
| 17 | Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. International Journal of Cancer, 1995, 63, 366-371. | 2.3 | 125 |
| 18 | Inhibition of Activated/Memory (CD45RO+) T Cells by Oxidative Stress Associated with Block of NF-ÎºB Activation. Journal of Immunology, 2001, 167, 2595-2601. | 0.4 | 121 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538. | 2.1 | 119 |
| 20 | Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production. Cancer Immunology Research, 2013, 1, 158-162. | 1.6 | 112 |
| 21 | Role of hsp60 during Autoimmune and Bacterial Inflammation. Immunological Reviews, 1991, 121, 91-111. | 2.8 | 110 |
| 22 | Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859. | 3.2 | 109 |
| 23 | Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. Journal of Translational Medicine, 2010, 8, 53. | 1.8 | 104 |
| 24 | Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 2017, 8, 21539-21553. | 0.8 | 103 |
| 25 | Tumor necrosis factor-Î± induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood, 2001, 98, 1108-1115. | 0.6 | 102 |
| 26 | Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32005-32016. | 3.3 | 89 |
| 27 | Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress. Journal of Immunology, 2008, 181, 8382-8390. | 0.4 | 81 |
| 28 | The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer. Journal of Immunology, 2013, 191, 6261-6272. | 0.4 | 79 |
| 29 | Counteracting CAR T cell dysfunction. Oncogene, 2021, 40, 421-435. | 2.6 | 76 |
| 30 | Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. , 1998, 78, 202-208. | | 75 |
| 31 | The CD16â˜'CD56bright NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16+CD56dim Subset. Journal of Immunology, 2007, 179, 4513-4519. | 0.4 | 73 |
| 32 | Cellular immunity to the Her-2/neu protooncogene. Advances in Cancer Research, 2002, 85, 101-144. | 1.9 | 72 |
| 33 | A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 1061-1071. | 2.0 | 68 |
| 34 | Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. OncoImmunology, 2012, 1, 1104-1110. | 2.1 | 64 |
| 35 | IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. OncoImmunology, 2017, 6, e1261242. | 2.1 | 59 |
| 36 | Increased susceptibility of ifn-Î³-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. International Journal of Cancer, 1991, 47, 527-532. | 2.3 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. International Journal of Cancer, 2000, 87, 349-359. | 2.3 | 57 |
| 38 | T cell recognition of HLAâ€A2 restricted tumor antigens is impaired by the oncogene HER2. International Journal of Cancer, 2011, 128, 390-401. | 2.3 | 53 |
| 39 | Laminins 411 and 421 differentially promote tumor cell migration via Î±6Î²1 integrin and MCAM (CD146). Matrix Biology, 2014, 38, 69-83. | 1.5 | 53 |
| 40 | T cell receptor diversity and activation markers in the VÎ´1 subset of rheumatoid synovial fluid and peripheral blood T lymphocytes. European Journal of Immunology, 1992, 22, 567-574. | 1.6 | 51 |
| 41 | HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. Journal of Immunology, 2012, 188, 2136-2145. | 0.4 | 51 |
| 42 | Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. OncoImmunology, 2016, 5, e1052213. | 2.1 | 51 |
| 43 | HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunology, Immunotherapy, 2009, 58, 653-664. | 2.0 | 48 |
| 44 | Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. OncoImmunology, 2016, 5, e1232222. | 2.1 | 48 |
| 45 | The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301. | 3.2 | 46 |
| 46 | Prognostic significance of tumor iNOS and COX-2 in stageÂIII malignant cutaneous melanoma. Cancer Immunology, Immunotherapy, 2009, 58, 1085-1094. | 2.0 | 44 |
| 47 | Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. , 2017, 5, 52. | | 42 |
| 48 | Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. Molecular Therapy, 2018, 26, 1482-1493. | 3.7 | 38 |
| 49 | Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Seminars in Immunopathology, 1996, 18, 227-242. | 4.0 | 36 |
| 50 | Dendritic cell regulation of NKâ€cell responses involves lymphotoxinâ€Î±, ILâ€12, and TGFâ€Î². European Journal of Immunology, 2015, 45, 1783-1793. | 1.6 | 34 |
| 51 | Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22910-22919. | 3.3 | 32 |
| 52 | Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunology, Immunotherapy, 2014, 63, 977-983. | 2.0 | 31 |
| 53 | Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-Î³ and multiple toll-like receptor agonists. Cancer Immunology, Immunotherapy, 2017, 66, 1333-1344. | 2.0 | 31 |
| 54 | Gamma-interferon (IFN-Î³) produced during effector and target interactions renders target cells less susceptible to NK-cell-mediated lysis. International Journal of Cancer, 1983, 32, 609-616. | 2.3 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. OncoImmunology, 2020, 9, 1792058. | 2.1 | 30 |
| 56 | PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. OncoImmunology, 2020, 9, 1786888. | 2.1 | 29 |
| 57 | Expression and prognostic significance of iNOS in uveal melanoma. International Journal of Cancer, 2010, 126, 2682-2689. | 2.3 | 28 |
| 58 | HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties. Journal of Biological Chemistry, 2012, 287, 24320-24329. | 1.6 | 28 |
| 59 | Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/NEU proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression. , 1997, 70, 112-119. | | 27 |
| 60 | The identification of a common pathogen-specific HLA classâ€„Iâ€„A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. European Journal of Immunology, 2001, 31, 3602-3611. | 1.6 | 26 |
| 61 | Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0139809. | 1.1 | 26 |
| 62 | Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. Cancer Immunology Research, 2018, 6, 1417-1425. | 1.6 | 25 |
| 63 | Antibody-Dependent Natural Killer Cellâ€“Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast Tumors. Cancer Research, 2010, 70, 7431-7441. | 0.4 | 24 |
| 64 | Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Frontiers in Immunology, 2019, 10, 2766. | 2.2 | 23 |
| 65 | Interleukinâ€33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophageâ€Mediated Shedding Mechanism. Advanced Science, 2021, 8, 2101029. | 5.6 | 20 |
| 66 | DNA Immunization of HLA Transgenic Mice with a Plasmid Expressing Mycobacterial Heat Shock Protein 65 Results in HLA Class I- and II-Restricted T Cell Responses That Can Be Augmented by Cytokines. Human Gene Therapy, 2001, 12, 1797-1804. | 1.4 | 19 |
| 67 | Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. , 2022, 10, e004458. | | 18 |
| 68 | Effect of IFN-Î³ treatment andin vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killef (LAK) cell lysisin vitro; association with H-2 expression on the target cells. International Journal of Cancer, 1989, 44, 669-674. | 2.3 | 17 |
| 69 | CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors. European Journal of Immunology, 1997, 27, 1988-1993. | 1.6 | 17 |
| 70 | The two sides of HER2/neu: immune escape versus surveillance. Trends in Molecular Medicine, 2013, 19, 677-684. | 3.5 | 17 |
| 71 | Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603. | | 17 |
| 72 | Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. OncoImmunology, 2021, 10, 1935557. | 2.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | NF-Î²B activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Human Vaccines and Immunotherapeutics, 2013, 9, 2189-2195. | 1.4 | 15 |
| 74 | Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. , 2021, 9, e002171. | | 12 |
| 75 | Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS. PLoS ONE, 2015, 10, e0129786. | 1.1 | 11 |
| 76 | Caveolin-1-Mediated Tumor Suppression Is Linked to Reduced HIF1Î± S-Nitrosylation and Transcriptional Activity in Hypoxia. Cancers, 2020, 12, 2349. | 1.7 | 11 |
| 77 | Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Oncotarget, 2016, 7, 52061-52084. | 0.8 | 11 |
| 78 | Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. OncoImmunology, 2022, 11, . | 2.1 | 9 |
| 79 | Interferon-Î³ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunology, Immunotherapy, 2006, 55, 653-662. | 2.0 | 8 |
| 80 | High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma. Cancer Immunology, Immunotherapy, 2020, 69, 513-522. | 2.0 | 6 |
| 81 | Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry. Methods in Molecular Biology, 2019, 1913, 181-194. | 0.4 | 5 |
| 82 | Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diganosed metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 3085-3085. | 0.8 | 5 |
| 83 | Myeloid Suppressors Decrease Melanoma Survival by Abating Tumor-Fighting T Cells. Clinical Cancer Research, 2014, 20, 1401-1403. | 3.2 | 3 |
| 84 | Assessment of Antitumor T-Cell Responses by Flow Cytometry After Coculture of Tumor Cells with Autologous Tumor-Infiltrating Lymphocytes. Methods in Molecular Biology, 2019, 1913, 133-140. | 0.4 | 3 |
| 85 | Opposing consequences of signaling through EGF family members. OncoImmunology, 2012, 1, 1200-1201. | 2.1 | 2 |
| 86 | Generation of Tumor-Specific Cytotoxic T Cells From Blood via InÂVitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads. Frontiers in Oncology, 2022, 12, 866763. | 1.3 | 2 |
| 87 | Response:Resistance of naturally occurring regulatory T cells toward oxidative stress: possible link with intracellular catecholamine content and implications for cancer therapy. Blood, 2009, 114, 488-489. | 0.6 | 1 |
| 88 | Designer lymphocytes to fight cancer: a helping hand from modern molecular biology. Journal of Molecular Medicine, 2010, 88, 1081-1084. | 1.7 | 1 |
| 89 | Cyclooxygenase-2. OncoImmunology, 2013, 2, e25157. | 2.1 | 1 |
| 90 | Establishment of Melanoma Tumor Xenograft Using Single Cell Line Suspension and Co-injection of Patient-Derived T Cells in Immune-Deficient NSG Mice. Methods in Molecular Biology, 2019, 1913, 207-215. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay. Methods in Molecular Biology, 2019, 1913, 167-179. | 0.4 | 1 |
| 92 | Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta OncolÃ³gica, 2022, 61, 869-873. | 0.8 | 1 |
| 93 | T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. Cancer Drug Discovery and Development, 2015, , 211-229. | 0.2 | 0 |